GG
RNTX

Gleason Group’s Rein Therapeutics RNTX Stock Holding History

Gleason Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3K Hold
22,389
– – ﹤0.01% 171
2026
Q1 		$29.1K Hold
22,389
– – ﹤0.01% 144
2025
Q4 		$26K Hold
22,389
– – ﹤0.01% 146
2025
Q3 		$25.6K Hold
22,389
– – ﹤0.01% 134
2025
Q2 		$31.3K Buy
+22,389
New +$40.3K ﹤0.01% 130

Other funds holding RNTX

SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Gleason Group's RNTX Position: Q2 2026 in Review

Gleason Group held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 22,389 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #171.

Gleason Group first reported a position in RNTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $31.3K in Q2 2025. 6 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Gleason Group held 22,389 shares of Rein Therapeutics worth $23.3K as of Q2 2026.
  • Gleason Group left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Gleason Group's portfolio in Q2 2026, its #171 holding.
  • Gleason Group first reported a position in Rein Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Gleason Group's Rein Therapeutics position peaked at $31.3K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Gleason Group's 13F filing for Q2 2026, filed 13 Jul 2026.